دورية أكاديمية

Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma.

التفاصيل البيبلوغرافية
العنوان: Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma.
المؤلفون: Piao GH; Department of Clinical Pathology, Yanbian Social Mental Hospital, Yanji City, China., Piao WH, He Y, Zhang HH, Wang GQ, Piao Z
المصدر: Histology and histopathology [Histol Histopathol] 2008 Oct; Vol. 23 (10), pp. 1171-5.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Histology and Histopathology Country of Publication: Spain NLM ID: 8609357 Publication Model: Print Cited Medium: Internet ISSN: 1699-5848 (Electronic) Linking ISSN: 02133911 NLM ISO Abbreviation: Histol Histopathol Subsets: MEDLINE
أسماء مطبوعة: Publication: Murcia : Histology and Histopathology
Original Publication: Murcia, Spain : Gutenberg, 1986-
مواضيع طبية MeSH: DNA Methylation* , Gene Expression Regulation, Neoplastic* , Gene Silencing* , Genes, Tumor Suppressor*, Carcinoma, Hepatocellular/*genetics , Cell Transformation, Neoplastic/*genetics , DNA-Binding Proteins/*genetics , Liver Neoplasms/*genetics , Nuclear Proteins/*genetics , Transcription Factors/*genetics, Carcinoma, Hepatocellular/pathology ; Cell Differentiation ; Cell Transformation, Neoplastic/pathology ; Histone-Lysine N-Methyltransferase ; Humans ; Liver Neoplasms/pathology ; Loss of Heterozygosity ; Neoplasm Staging ; Polymerase Chain Reaction ; Promoter Regions, Genetic
مستخلص: The retinoblastoma protein-interacting zinc finger gene RIZ1 is a putative tumor suppressor gene, and the inactivation of the RIZ1 is frequently found in tumors through a loss of mRNA expression. In order to understand the role of RIZ1 inactivation in the tumorigenesis of hepatocellular carcinoma (HCC), we detected the RIZ1 promoter methylation status in 39 HCCs using a methylation specific PCR (MSP) method, and carried out LOH study with marker P704. We also assessed the associations between the methylation status and clinicopathological parameters, tumor size, tumor differentiation, and fractional allelic loss (FAL). The results showed that the RIZ1 promoter methylated both in advanced tumors (>3 cm), (18/31, 58.0%) and in early tumors (<3 cm), (4/8, 50.0%). There were 54.6% (12/22) tumors with hyper-methylation in the low FAL group and 45.5% (10/22) in the high FAL group. Moreover, the DNA methylation of the RIZ1 promoter was found not only in the poorly differentiated tumors (12/22, 54.6%), but also in the well differentiated tumors (10/22, 45.5%). Among the 22 HCCs (22/39, 56.4%) that showed hyper-methylation at the RIZ1 promoter region, 3 cases showed biallelic methylation. Interestingly, one case showed hyper-methylation on one allele and a loss of heterozygosity (LOH) on the other allele. In other words, 4 HCCs showed the biallelic inactivation of the RIZ1. These results suggest that the inactivation of the RIZ1 by DNA methylation at its promoter region is involved in the tumorigenesis of HCC, particularly in the early stage of disease.
المشرفين على المادة: 0 (DNA-Binding Proteins)
0 (Nuclear Proteins)
0 (Transcription Factors)
EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
EC 2.1.1.43 (PRDM2 protein, human)
تواريخ الأحداث: Date Created: 20080821 Date Completed: 20081023 Latest Revision: 20170222
رمز التحديث: 20240628
DOI: 10.14670/HH-23.1171
PMID: 18712668
قاعدة البيانات: MEDLINE
الوصف
تدمد:1699-5848
DOI:10.14670/HH-23.1171